IMMUTEP Ltd 20-F for FY2026
IMMUTEP Ltd (IMMP)
20-F
2026-10-23
For: 2026-06-30
View Original
Added on
October 23, 2026
About this 20-F
IMMUTEP Ltd filed this 20-F on October 23, 2026, covering the fiscal year ended June 30, 2026 (FY2026).
Immutep discontinued the TACTI-004 Phase III trial in March 2026, repaid Dr. Reddy’s US$10.0 million, and reported a fiscal year 2026 net loss of A$79.3 million. A$68.9 million in cash and term deposits was expected to support operations into the first half of calendar year 2028. AI summary
Headline figures
Fiscal year ended June 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- 24.17M AUD
- up 133.9% from 10.33M AUD a year earlier
- Net loss
- 79.3M AUD
- compared with a net loss of 61.43M AUD a year earlier
- Diluted EPS
- -0.05 AUD
- compared with -0.04 AUD a year earlier